崇明县优米一站美甲加盟电话多少钱(梁平区u3美甲加盟电话多少钱) (今日更新中)

MOSCOW, May 13 (Xinhua) -- The main and backup crews that will fly to the International Space Station in June have passed preflight tests and are ready for space travel, the Russian Cosmonauts Training Center said Friday.The main crew includes Russian cosmonaut Sergei Volkov, Japanese astronaut Satoshi Furukawa and American astronaut Michael Fossuma.A Russian spaceship Soyuz TMA-02M will send the crew to the space station on June 8, Interfax news agency reported.The backup crew includes members from Russia, the Netherlands and the United States.The crews were tested on the various emergency situations they could face during the flight.Next Monday, the commission will make a final choice of crewmembers for the launch.The crew will spend 161 days in orbit and conduct three space walks.

WELLINGTON, May 13 (Xinhua) -- While it's long been known that a little sunshine can spread happiness, researchers in New Zealand have found that it can also save the lives of pneumonia patients.Medical scientists have found that vitamin D, which is absorbed through the skin and produced with exposure to sunlight, is a major factor in the survival rate of pneumonia patients.Researchers at Waikato University collaborated with doctors at Waikato Hospital, both Hamilton-based institutions, to study blood samples of 112 patients admitted to the hospital with pneumonia during the winter.They found that those with severe vitamin D deficiency 17 of the patients were more likely to die within a month, compared with patients with normal or slightly low vitamin D levels.Dr Bob Hancox, of the hospital's department of respiratory medicine, said five of the 17 died, a 29-percent mortality rate, compared with four deaths among the 95 patients with higher vitamin D levels, a 4-percent mortality rate."The analysis confirmed that the difference in mortality rates between the two groups was very unlikely to be due to chance," Hancox told Xinhua.Vitamin D deficiency was a concern around the world, Hancox said."Sunlight is the main source of vitamin D, so it tends to be a winter problem in temperate climates when people spend a lot of time indoors. But it occurs in all countries and vitamin D deficiency is believed to be a major problem worldwide."There is accumulating evidence that we need vitamin D to help fight infections, such as pneumonia as we have shown, as well as improve bone health," he told Xinhua."What is not yet clear is whether we can do anything about it. We don't know whether treating people with vitamin D supplements would help to prevent or treat respiratory infections. This is what we need to find out now."Dr Ray Cursons, of the Biological Sciences department at Waikato University, said patient age, sex, additional health conditions, and other prognostic factors did not affect the research outcome, although researchers still could not establish a causal link between vitamin D deficiency and mortality in the patients.Waikato Hospital D respiratory specialist Dr Noel Karalus said it was not yet known whether giving patients vitamin D supplements after their admission to hospital with respiratory tract infections would alter outcomes."It may transpire that vitamin D helps us avoid infection rather than cure it once established."Cursons said the best source of vitamin D was sunlight as dietary sources such as fatty fish and cod liver oil did not contain enough vitamin D."There is still some controversy regarding the optimal daily allowance of vitamin D. How much we absorb through the skin depends on sun exposure, skin type and geographical latitude. M ori and Pacific Islanders absorb less because of their darker skin, and people in colder climates also have lower levels of vitamin D. "Pneumonia is the single largest cause of death in children worldwide, killing an estimated 1.6 million children under the age of five each year, according to the World Health Organization.The research findings are published in the journal Respirology, published by the Asian Pacific Society of Respirology, this month.

BEIJING, May 24 (Xinhuanet) -- Scientists revealed for the first time the molecular structure of proteins, which enables bacteria to transfer electrical charges, according to a new study. The revelation was published in Proceedings of the National Academy of Sciences in the U.S. on Monday.Scientists used a technique called "x-ray crystallography" to reveal the molecular structure of proteins, which work as atom-sized "wires" discharging excess electricity."This is an exciting advance in our understanding of how some bacterial species move electrons from the inside to the outside of a cell," said lead author Tom Clarke of the University of East Anglia's School of Biological Sciences in Norwich, England.He said this discovery means "We can now start developing efficient 'bio-batteries' as the viable energy source in the future."Still, it could take perhaps a decade to go. Before that, existing uses of such bacteria needed to become 100 or 1,000 times more efficient, he said.The advance could also hasten the development of microbe technology that can help clean up oil or uranium pollution, he said.Microbes might in future be enlisted to clean up nuclear accidents such as Japan's Fukushima Daiichi disaster, he added.

BRUSSELS, April 29 (Xinhua) -- As a 2004 European Union (EU) directive on herbal medicine is to be fully implemented on May 1, herbal medicinal products without a license will no longer be allowed in the EU market, the European Commission said in a press release Friday.The Traditional Herbal Medicinal Products Directive, adopted by the EU member states in 2004, introduced a so-called simplified registration procedure with a seven-year transition period for traditional herbal medicinal products to obtain a medicine license.As the transition period is to expire on Saturday, herbal medicinal products from home and abroad, most of which have been sold as food supplements for decades, need to be medically registered or authorized by EU governments in order to remain in the market after May 1.Instead of going through safety tests and clinical trials as regular chemical drugs, applicants are required by the directive to provide documents showing the herbal medicinal product is not harmful in the specified condition of use, as well as evidence that the product at least has a 30-year history of safe use, including 15 years in the EU.However, a wide range of eligibility and technical challenges along with prohibitive costs have so far prevented both local and outside herbal medicinal products from being granted the license.Only a small proportion of indigenous herbal medicinal products have been approved for registration while not a single Chinese or Indian traditional herbal medicinal products have been licensed.Lack of pan-European rules, EU member states had adopted different approaches to herbal medicine, thus creating a "state of anarchy" in the markets despite the fact that indigenous herbs had a 700-year history of use in Europe.Although the directive was intended to harmonize rules of member states and build a level-playing field across the EU, critics argued that the directive may fall short of the aim and create more chaos and uncertainties for the industry.DRAWBACKSThe directive has been under attack for being neither "adequate " nor "appropriate" due to its high registration cost for a single product and its lack of consideration about the Chinese and Indian traditional herbal medicine.Chris Dhaenens, a licensed herbalist in Belgium and a shareholder of a medium-sized herbal importing company doing business with China and ten European countries, said the directive was only appropriate for companies carrying a few products and who could afford the registration costs."It is simply inaccessible to most players distributing high- quality Chinese or Indian herbal products in Europe," he said, adding that the registration fee for a single product could be as high as 150,000 euros.The Alliance for Natural Health, a British-based group representing herbal practitioners, estimated the cost of obtaining a license at between 80,000 and 120,000 pounds (90,000 to 135,000 U.S. dollars) per herb.Dhaenens, who is also the president of the European Benefyt Foundation, a leading traditional medicine group in Europe, argued that the directive only tried to regulate herbal products instead of its practitioners and the whole herbal system, as well as fell short to take the Chinese and Indian traditional medicine into full consideration.Even the European Commission had admitted that the directive was not fit for the registration of Chinese and Indian medicine in an earlier exchange with the European Medicine Agency in Dec. 2008, Dhaenens revealed in an exclusive interview with Xinhua."But they had no money or time to work out an alternative, and so it was left to the member states," he said.

来源：资阳报